Mersana Therapeutics, Inc. (MRSN) News
Filter MRSN News Items
MRSN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MRSN News From Around the Web
Below are the latest news stories about MERSANA THERAPEUTICS INC that investors may wish to consider to help them evaluate MRSN as an investment opportunity.
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on December 1, 2023, the Compensation Committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 12,205 shares of its common |
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call TranscriptMersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript November 7, 2023 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.31. Operator: Good morning, and welcome to the Mersana Therapeutics Third Quarter 2023 Conference Call and Webcast. [Operator Instructions]. Please note, this call is being recorded. I would now like to […] |
Q3 2023 Mersana Therapeutics Inc Earnings CallQ3 2023 Mersana Therapeutics Inc Earnings Call |
Mersana Therapeutics Inc (MRSN) Reports Q3 2023 Financial ResultsCompany's Q3 2023 Earnings Highlight Progress in Clinical Trials and Strategic Priorities |
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial ResultsAdvancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADCPreparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2 Immunosynthen ADCCapital resources expected to support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering a |
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2023 on Tuesday, November 7, 2023. The company will host a conference call and webcast at 8:00 |
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company’s Phase 1 clinical trial of XMT-2056. XMT-2056 is a systemically administered Immunosynthen STING-agonist ADC that |
The Petri Dish: Biogen secures $1.5B loan; Mersana CEO departs after trial failureBiogen is acquiring Reata Pharmaceuticals with the help of a hefty loan, Novo Nordisk teams up with the Broad Institute and other life sciences news you may have missed. |
Mersana Therapeutics Announces Changes in LeadershipDr. Martin Huber Martin Huber, M.D., has been named President and Chief Executive Officer of Mersana Therapeutics, Inc., effective September 11, 2023. Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., named Chief Development Officer CAMBRIDGE, Mass., Sept. 06, 2023 (GLOB |
After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN)The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |